Datapoint: Lilly Scores UC Nod for Omvoh

After a long wait and previous rejection, the FDA on Oct. 26 approved Lilly’s Omvoh for the treatment of moderately to severely active ulcerative colitis (UC) in adults. The drug is the first interleukin-23p19 (IL-23p19) antagonist approved to treat UC, and is first administered via infusions, then self-injections as maintenance requires. Among the most advantaged ulcerative colitis therapies covered under the medical benefit are tumor necrosis factor-alpha blockers, such as Johnson & Johnson’s Remicade, which holds covered or better status for 94% of insured lives, Merck’s Remicade biosimilar Renflexis (92%) and Pfizer’s Remicade biosimilar Inflectra (91%).

SOURCE: MMIT Analytics, as of 10/30/23

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 28

Datapoint: Froedtert Health Set to Acquire Wisconsin Insurer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 27

Datapoint: Express Scripts to Offer New “Cost-Plus” Pricing Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 16

Datapoint: Novo Nordisk Says Most People Are Paying Less Than $25 a Month for Wegovy

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today